Omacetaxine
Refractory Acute Leukemia
The First Affiliated Hospital of Soochow UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Refractory Acute Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
5-azacytidine The First Affiliated Hospital of Soochow University | Phase 2 | CCC |
Mitoxantrone Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1/2 | CCC |
Quizartinib M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Same molecule, other indications
Omacetaxine is also rated in:
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →